Texas uni wants Supreme Court to settle state sovereignty rules

The University of Texas has asked the Supreme Court to rule that state-owned institutions should escape the normal rules determining the appropriate venue for filing patent lawsuits.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Texas court awards $41m to US biotech

21 July 2022 Japan-based pharma company must pay for infringment | Drug was recently approved for breast cancer treatment by EU.

Americas

Texas Uni’s sovereign immunity fail went as expected

4 March 2021 The result of the sovereign immunity bid mirrored previous cases but we did learn something about the opinions of Justices on the issue, says Gary Frischling of Milbank.

Biotechnology

Texas uni loses bid to shield cancer vaccine patents from IPRs

18 February 2021 The University of Texas has failed to persuade the US Court of Appeals for the Federal Circuit to review a ruling that prevented it from using sovereign immunity to protect its cancer vaccine patents from inter partes reviews.

More on this story

Americas

Texas court awards $41m to US biotech

21 July 2022 Japan-based pharma company must pay for infringment | Drug was recently approved for breast cancer treatment by EU.

Americas

Texas Uni’s sovereign immunity fail went as expected

4 March 2021 The result of the sovereign immunity bid mirrored previous cases but we did learn something about the opinions of Justices on the issue, says Gary Frischling of Milbank.

Biotechnology

Texas uni loses bid to shield cancer vaccine patents from IPRs

More on this story

Americas

Texas court awards $41m to US biotech

21 July 2022 Japan-based pharma company must pay for infringment | Drug was recently approved for breast cancer treatment by EU.

Americas

Texas Uni’s sovereign immunity fail went as expected

4 March 2021 The result of the sovereign immunity bid mirrored previous cases but we did learn something about the opinions of Justices on the issue, says Gary Frischling of Milbank.

Biotechnology

Texas uni loses bid to shield cancer vaccine patents from IPRs